Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.
Andrew Weiss, head of pharma and biotech research at Vontobel, tells CNBC why Novartis' failure to win its battle for patent protection for the drug Glivec highlights the flaws in pharma companies' emerging market strategy.
Looking for a small stock with big return potential? Jim Cramer thinks you should consider this.
India's top court has dealt a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
A new study indicates that Obama's health care overhaul will result in a 32 percent claims cost increase which could translate into higher premiums for Americans.
Federal regulators are pressing the Supreme Court to stop big pharmaceuticals from paying generic drug competitors to delay releasing cheaper versions of brand-name drugs.
The Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market.
Discussing health care in China, the promotion of female executives, and the state of his business, with Cardinal Health CEO George Barrett. "Health care in China has been a tremendous opportunity for our company," he says.
Walgreen and partner Alliance Boots will take up to a 23 percent stake in AmerisourceBergen, ending Walgreen's current contract with Cardinal Health.
Like all computers, Intuitive Surgical's da Vinci robot can malfunction during surgery. A range of results have been reported by surgeons.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
Congress wants a second look at how private firms profit from public research after Pfizer and the National Institutes of Health developed a potentially lucrative new drug. The NYT reports.
Obamacare and the aging of doctors and patients are exacerbating the shortage of primary care physicians.
Spending on drugs to treat common diseases fell 1.5 percent among customers who receive prescription benefits through commercial insurers.
Moves by Indonesia's President Susilo Bambang Yudhoyono to put his finance minister in charge of the central bank is leading to concerns that he may be seeking someone more malleable to run the state coffers in the run up to next year's elections.
A baby girl in Mississippi who was born with HIV has been cured after very early treatment with standard HIV drugs, U.S. researchers reported on Sunday.
If you smoke, you might have to pay thousands extra for employee-based health insurance under Obamacare starting next year.
The Obama administration has outlined the essential health benefits that insurers must offer to consumers in individual and small group markets under Obamacare.
Dr Amit Roy, managing director and head of healthcare research at Nomura, tells CNBC that the ability to keep making new blockbuster drugs depends on the medicine.